Clinical Trials Logo

Clinical Trial Summary

This is an open-label, randomized, single-center, 2-period, 2-sequence, single-dose crossover design study in adult male and female healthy participants. Eligible participants will receive either treatment A (reference): Fluimucil® Acetylcysteine 2% oral solution, 200 mg N- acetylcysteine (NAC) in 10 mL dose, or treatment B (test): Acetylcysteine 2% oral solution, 200 mg NAC in 10 mL dose. Blood sampling will be collected pre-dose and up to 48 hours in each period. After completion of the second study period (i.e. last pharmacokinetic (PK) sample on Day 3 of Period 2) participants will be discharged from the clinic.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02688361
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date February 22, 2016
Completion date April 13, 2016

See also
  Status Clinical Trial Phase
Completed NCT02202187 - A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT02257398 - Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT01706315 - This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects Phase 1
Completed NCT02000765 - A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects Phase 1
Completed NCT04600752 - Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India Phase 4
Terminated NCT01292213 - A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom N/A
Completed NCT01772238 - Bioequivalence Study of an Amoxicillin-Clavulanic Phase 1
Completed NCT01615796 - Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses Phase 1
Completed NCT02169583 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Phase 1
Completed NCT01353768 - Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study N/A
Completed NCT01767571 - Bioequivalence Study of Cephalexin Suspension 250 Phase 1
Completed NCT01767532 - Bioequivalence Study of Cephalexin Suspension 125 Phase 1
Completed NCT01510938 - Probiotics in Respiratory Tract Infections in Children Phase 2
Completed NCT00354965 - Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients Phase 1
Withdrawn NCT02678234 - An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu Phase 3
Withdrawn NCT02730364 - An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu Phase 3
Completed NCT01767584 - Bioequivalence Study of Cephalexin Tablets 1g Phase 1